Estradiol therapy and breast cancer risk in perimenopausal and postmenopausal women: a systematic review and meta-analysis

References

• Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997;350:1047–59.
   PubMed Web of Science ®Google Scholar
• Stuenkel CA, Davis SR, Gompel A, et al. Treatment of symptoms of the menopause: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2015;100:3975–4011.
   PubMed Web of Science ®Google Scholar
• Panay N, Ylikorkala O, Archer DF, et al. Ultra-low-dose estradiol and norethisterone acetate: effective menopausal symptom relief. Climacteric 2007;10:120–31.
   PubMed Web of Science ®Google Scholar
• The Practice Committee of the American Society for Reproductive Medicine. Estrogen and progestogen therapy in postmenopausal women. Fertil Steril 2006;86:S75–88.
   Google Scholar
• Santen RJ, Allred DC, Ardoin SP, et al. Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab 2010;95:s1–66.
   PubMed Web of Science ®Google Scholar
• Chlebowski RT, Manson JAE, Anderson GL, et al. Estrogen plus progestogen and breast cancer incidence and mortality in the Women's Health Initiative observational study. J Natl Cancer Inst 2013;105:526–35.
   PubMed Web of Science ®Google Scholar
• Porch JV, Lee IM, Cook NR, et al. Estrogen-progestogen replacement therapy and breast cancer risk: the Women's Health Study (United States). Cancer Causes Control 2002;13:847–54.
   PubMed Web of Science ®Google Scholar
• Anderson GL, Chlebowski RT, Rossouw JE, et al. Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin. Maturitas 2006;55:103–15.
   PubMed Web of Science ®Google Scholar
• Chlebowski RT, Anderson GL, Gass M, et al. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA 2010;304:1684–92.
   PubMed Web of Science ®Google Scholar
• Hulley S, Furberg C, Barrett-Connor E, et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: heart and estrogen/progestogen replacement study follow-up (HERS II). JAMA 2002;288:58–66.
   PubMed Web of Science ®Google Scholar
• Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:1330.
   Web of Science ®Google Scholar
• Vickers MR, Martin J, Meade TW, et al. The women’s international study of long duration estrogen after menopause (WISDOM): a randomized controlled trial. BMC Women’s Health 2007; 7:1–17.
   PubMedGoogle Scholar
• Collins JA, Crosignani PG, Blake JM, et al. Breast cancer risk with postmenopausal hormonal treatment. Hum Reprod Update 2005;11:545–60.
   PubMed Web of Science ®Google Scholar
• Shah NR, Borenstein J, Dubois RW, et al. Postmenopausal hormone therapy and breast cancer: a systematic review and meta-analysis. Menopause 2005;12:668–78.
   PubMed Web of Science ®Google Scholar
• Karim R, Mack WJ, Lobo RA, et al. Determinants of the effect of estrogen on the progression of subclinical atherosclerosis: estrogen in the prevention of atherosclerosis trial. Menopause 2005;12:366–73.
   PubMed Web of Science ®Google Scholar
• Humphrey LL, Hormone replacement therapy and breast cancer: systematic evidence review number 14. Rockville, MD: Agency for Health Care Research and Quality, US Department of Health and Human Services; 2002.
   Google Scholar
• Lee SA, Ross RK, Pike MC, et al. An overview of menopausal oestrogen-progestin hormone therapy and breast cancer risk. Br J Cancer 2005;92:2049–58.
   PubMed Web of Science ®Google Scholar
• Marjoribanks J, Farquhar C, Roberts H, et al. Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev 2012;7:CD004143.
   PubMed Web of Science ®Google Scholar
• Nelson HD, Walker M, Zakher, et al. Menopausal hormone therapy for the primary prevention of chronic conditions: a systematic review to update the US preventive services task force recommendations. Ann Intern Med 2012;157:104–13.
   PubMed Web of Science ®Google Scholar
• Khalid B, Khaled M, Alaa AN, et al. Menopausal hormone therapy and mortality: a systematic review and meta-analysis. J Clin Endocrinol Metabol 2015;100:4021–8.
   PubMed Web of Science ®Google Scholar
• Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928.
   PubMed Web of Science ®Google Scholar
• Savović J, Weeks L, Sterne JA, et al. Evaluation of the Cochrane Collaboration’s tool for assessing the risk of bias in randomized trials: focus groups, online survey, proposed recommendations and their implementation. Syst Rev 2014;3:1–12.
   PubMedGoogle Scholar
• Wells GA, O'Connell D, Peterson J, et al The Newcastle–Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. UK: University of Liverpool; 2000.
   Google Scholar
• DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177–18.
   PubMed Web of Science ®Google Scholar
• Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003;327:557–60.
   PubMed Web of Science ®Google Scholar
• Shi X. Comparison of the power difference of egger’s test and Begg’s test and the reason analysis. Acta Med Univ Scientiae Et Technol Huazhong 2009;38:91–3
   Google Scholar
• Viscoli CM, Brass LM, Kernan WN, et al. A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med 2001;345:1243–49.
   PubMed Web of Science ®Google Scholar
• Notelovitz M, John VA, Good WR, et al. Effectiveness of Alora estradiol matrix transdermal delivery system in improving lumbar bone mineral density in health postmenopausal women. Menopause 2002;9:343–53.
   PubMed Web of Science ®Google Scholar
• Hodis HN, Mack WJ, Azen SP, et al. Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women. N Engl J Med 2003;349:535–45.
   PubMed Web of Science ®Google Scholar
• Grady D, Vittinghoff E, Lin F, et al. Effect of ultra-low-dose transdermal estradiol on breast density in postmenopausal women. Menopause 2007;14:391–6.
   PubMed Web of Science ®Google Scholar
• Cherry N, McNamee R, Heagerty A, et al. Long-term safety of unopposed estrogen used by women surviving myocardial infarction: 14-year follow-up of the ESPRIT randomized controlled trial. BJOG 2014;121:700–5.
   PubMed Web of Science ®Google Scholar
• Olsson HL, Ingvar C, Bladstrom A, et al. Hormone replacement therapy containing progestins and given continuously increases breast carcinoma risk in Sweden. Cancer 2003;97:1387–92.
   PubMed Web of Science ®Google Scholar
• Jernstrom H, Bendahl PO, Lidfeldt J, et al. A prospective study of different types of hormone replacement therapy use and the risk of subsequent breast cancer: the women’s health in the Lund area (WHILA) study (Sweden). Cancer Causes Control 2003;14:673–80.
   PubMed Web of Science ®Google Scholar
• Stahlberg C, Pedersen AT, Lynge E, et al. Increased risk of breast cancer following different regimens of hormone replacement therapy frequently used in Europe. Int J Cancer 2004;109:721–7.
   PubMed Web of Science ®Google Scholar
• Bakken K, Alsaker E, Eggen AE, et al. Hormone replacement therapy and incidence of hormone-dependent cancers in the Norwegian women and cancer study. Int J Cancer 2004;112:130–4.
   PubMed Web of Science ®Google Scholar
• Espie M, Daures JP, Chevallier T, et al. Breast cancer incidence and hormone replacement therapy: results from the MISSION study, prospective phase. Gynecol Endocrinol 2007;23:391–7.
   PubMed Web of Science ®Google Scholar
• Fournier A, Berrino F, Clavel-Chapelon F, et al. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat 2008;107:103–11.
   PubMed Web of Science ®Google Scholar
• Persson I, Thurf J, Bergstro R, et al. Hormone replacement therapy and the risk of breast cancer: nested case-control study in a cohort of Swedish women attending mammography screening. Int J Cancer 1997;72:758–61.
   PubMed Web of Science ®Google Scholar
• Schneider C, Jick SS, Meier CR, et al. Risk of gynecological cancers in users of estradiol/dydrogesterone or other HRT preparations. Climacteric 2009;12:514–24.
   PubMed Web of Science ®Google Scholar
• Lyytinen H, KDyba T, Ylikorkala O, et al. A case-control study on hormone therapy as a risk factor for breast cancer in Finland: intrauterine system carries a risk as well. Int J Cancer 2010;126:483–9.
   PubMed Web of Science ®Google Scholar
• Bakken K, Fournier A, Lund E, et al. Menopausal hormone therapy and breast cancer risk: impact of different treatments. The European Prospective Investigation into Cancer and Nutrition. Int J Cancer 2011;128:144–56.
   PubMed Web of Science ®Google Scholar
• Anderson TJ, Battersby S, King RJB, et al. Oral contraceptive use influences resting breast proliferation. Hum Pathol 1989;20:1139–44.
   PubMed Web of Science ®Google Scholar
• Lange CA, Richer JK, Horwitz KB, et al. Hypothesis: progesterone primes breast cancer cells for cross-talk with proliferative or antiproliferative signals. Mol Endocrinol 1999;13:829–36.
   PubMed Web of Science ®Google Scholar
• Druckmann R. Progestogens and their effects on the breast. Maturitas 2003;46:S59–69.
   PubMedGoogle Scholar
• Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 2009;62:e1–34.
   PubMed Web of Science ®Google Scholar